Determining the best length of antibiotic treatment for kidney transplant infections
Planning an antibiotic duration trial for acute graft pyelonephritis after kidney transplantation
This study is looking at how long kidney transplant patients should take antibiotics for a common infection called acute graft pyelonephritis, to find the shortest time that still keeps them safe and healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10690286 on NIH RePORTER |
What this research studies
This research aims to find the optimal duration of antibiotic treatment for acute graft pyelonephritis, a common infection that can occur after kidney transplantation. The study will involve a multi-center, randomized trial where patients will be assigned to different treatment durations ranging from 7 to 21 days. By comparing these durations, the researchers hope to identify the shortest effective treatment that minimizes side effects and costs while maintaining patient safety. This approach is designed to improve care for kidney transplant recipients who are at risk for serious infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently undergone kidney transplantation and are experiencing acute graft pyelonephritis.
Not a fit: Patients who are not kidney transplant recipients or those who do not have acute graft pyelonephritis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer antibiotic treatment protocols for kidney transplant recipients, reducing the risk of complications.
How similar studies have performed: Previous research has shown that optimizing antibiotic treatment durations can lead to better patient outcomes, suggesting that this approach has potential for success.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Van Duin, David — Univ of North Carolina Chapel Hill
- Study coordinator: Van Duin, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.